Apellis Pharmaceuticals Inc (APLS)
41.95
+0.75
(+1.82%)
USD |
NASDAQ |
May 15, 14:20
Apellis Pharmaceuticals Total Assets (Quarterly): 831.93M for March 31, 2024
Total Assets (Quarterly) Chart
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 831.93M |
| December 31, 2023 | 788.73M |
| September 30, 2023 | 818.22M |
| June 30, 2023 | 915.58M |
| March 31, 2023 | 978.87M |
| December 31, 2022 | 760.22M |
| September 30, 2022 | 872.89M |
| June 30, 2022 | 1.002B |
| March 31, 2022 | 1.146B |
| December 31, 2021 | 881.76M |
| September 30, 2021 | 525.69M |
| June 30, 2021 | 699.91M |
| March 31, 2021 | 810.13M |
| December 31, 2020 | 960.57M |
| September 30, 2020 | 768.33M |
| June 30, 2020 | 870.11M |
| March 31, 2020 | 688.94M |
| Date | Value |
|---|---|
| December 31, 2019 | 389.24M |
| September 30, 2019 | 466.36M |
| June 30, 2019 | 316.70M |
| March 31, 2019 | 318.35M |
| December 31, 2018 | 203.53M |
| September 30, 2018 | 239.15M |
| June 30, 2018 | 266.82M |
| March 31, 2018 | 163.20M |
| December 31, 2017 | 182.13M |
| September 30, 2017 | 19.14M |
| June 30, 2017 | 56.69M |
| December 31, 2016 | 27.43M |
| December 31, 2015 | 38.18M |
| September 30, 2015 | 13.74M |
| June 30, 2015 | 16.82M |
| December 31, 2014 | 14.31M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
316.70M
Minimum
Jun 2019
1.146B
Maximum
Mar 2022
774.63M
Average
814.17M
Median
Total Assets (Quarterly) Benchmarks
| Blueprint Medicines Corp | 1.038B |
| Sarepta Therapeutics Inc | 3.224B |
| Inspire Medical Systems Inc | 685.84M |
| Alnylam Pharmaceuticals Inc | 3.824B |
| Biomarin Pharmaceutical Inc | 6.873B |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 565.25M |
| Shareholders Equity (Quarterly) | 266.68M |
| Debt to Equity Ratio | 0.3491 |
| Current Ratio | 3.769 |
| Net Debt Paydown Yield | -0.00% |